Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemed Co. stock logo
CHE
Chemed
$555.18
+1.3%
$592.93
$492.84
$654.62
$8.41B0.4680,483 shs106,617 shs
Encompass Health Co. stock logo
EHC
Encompass Health
$86.40
+0.9%
$82.83
$57.55
$87.94
$8.70B0.92634,855 shs545,749 shs
Select Medical Holdings Co. stock logo
SEM
Select Medical
$34.55
+1.9%
$30.45
$21.28
$35.08
$4.49B1.38578,431 shs464,367 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$62.26
+0.8%
$71.58
$8.28
$99.41
$6.87B1.125.03 million shs2.19 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemed Co. stock logo
CHE
Chemed
+1.49%-1.12%-3.43%-10.62%+2.78%
Encompass Health Co. stock logo
EHC
Encompass Health
+1.60%+1.25%+2.64%+15.38%+37.99%
Select Medical Holdings Co. stock logo
SEM
Select Medical
+1.59%+2.91%+19.68%+25.10%+24.00%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-3.18%+0.34%-22.37%-27.51%+181.33%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chemed Co. stock logo
CHE
Chemed
4.8342 of 5 stars
2.53.03.34.92.72.52.5
Encompass Health Co. stock logo
EHC
Encompass Health
4.7491 of 5 stars
1.65.01.75.03.33.32.5
Select Medical Holdings Co. stock logo
SEM
Select Medical
4.547 of 5 stars
1.34.02.54.82.73.32.5
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.3726 of 5 stars
4.62.00.04.72.22.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chemed Co. stock logo
CHE
Chemed
3.00
Buy$673.5021.31% Upside
Encompass Health Co. stock logo
EHC
Encompass Health
3.13
Buy$92.006.48% Upside
Select Medical Holdings Co. stock logo
SEM
Select Medical
2.50
Moderate Buy$34.25-0.87% Downside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.11
Buy$112.3880.49% Upside

Current Analyst Ratings

Latest EHC, SEM, VKTX, and CHE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2024
Encompass Health Co. stock logo
EHC
Encompass Health
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$83.00 ➝ $95.00
5/21/2024
Chemed Co. stock logo
CHE
Chemed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$712.00 ➝ $697.00
5/16/2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Strong-Buy$115.00 ➝ $116.00
5/16/2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00
5/6/2024
Select Medical Holdings Co. stock logo
SEM
Select Medical
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$36.00 ➝ $40.00
5/3/2024
Select Medical Holdings Co. stock logo
SEM
Select Medical
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$39.00 ➝ $39.00
4/26/2024
Encompass Health Co. stock logo
EHC
Encompass Health
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$85.00 ➝ $95.00
4/25/2024
Encompass Health Co. stock logo
EHC
Encompass Health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$101.00 ➝ $108.00
4/25/2024
Encompass Health Co. stock logo
EHC
Encompass Health
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$93.00 ➝ $95.00
4/25/2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
4/12/2024
Select Medical Holdings Co. stock logo
SEM
Select Medical
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$39.00
(Data available from 5/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chemed Co. stock logo
CHE
Chemed
$2.26B3.71$25.22 per share22.01$78.17 per share7.10
Encompass Health Co. stock logo
EHC
Encompass Health
$4.80B1.81$6.68 per share12.94$23.46 per share3.68
Select Medical Holdings Co. stock logo
SEM
Select Medical
$6.66B0.67$3.75 per share9.21$12.59 per share2.74
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$8.47 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chemed Co. stock logo
CHE
Chemed
$272.51M$18.5829.8823.152.2112.36%30.52%20.13%7/24/2024 (Estimated)
Encompass Health Co. stock logo
EHC
Encompass Health
$352M$3.7023.3518.911.317.60%18.01%6.55%8/6/2024 (Estimated)
Select Medical Holdings Co. stock logo
SEM
Select Medical
$243.49M$2.1016.4514.641.583.97%18.11%3.64%8/1/2024 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$85.89M-$0.93N/AN/AN/AN/A-18.41%-17.69%7/24/2024 (Estimated)

Latest EHC, SEM, VKTX, and CHE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q1 2024
Select Medical Holdings Co. stock logo
SEM
Select Medical
$0.55$0.77+$0.22$0.79$1.70 billion$1.79 billion
4/24/2024Q1 2024
Chemed Co. stock logo
CHE
Chemed
$5.09$4.68-$0.41$5.12$587.18 million$589.23 million    
4/24/2024Q1 2024
Encompass Health Co. stock logo
EHC
Encompass Health
$0.93$1.12+$0.19$1.14$1.27 billion$1.32 billion    
4/24/2024Q1 2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.27-$0.26+$0.01-$0.26N/AN/A    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chemed Co. stock logo
CHE
Chemed
$1.600.29%+5.73%8.61%15 Years
Encompass Health Co. stock logo
EHC
Encompass Health
$0.600.69%-18.78%16.22%1 Years
Select Medical Holdings Co. stock logo
SEM
Select Medical
$0.501.45%N/A23.81%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest EHC, SEM, VKTX, and CHE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2024
Encompass Health Co. stock logo
EHC
Encompass Health
Quarterly$0.150.72%6/28/20247/1/20247/15/2024
5/20/2024
Chemed Co. stock logo
CHE
Chemed
quarterly$0.400.3%5/30/20245/30/20246/18/2024
5/2/2024
Select Medical Holdings Co. stock logo
SEM
Select Medical
Quarterly$0.12501.59%5/15/20245/16/20245/30/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chemed Co. stock logo
CHE
Chemed
N/A
1.91
1.88
Encompass Health Co. stock logo
EHC
Encompass Health
1.14
1.37
1.37
Select Medical Holdings Co. stock logo
SEM
Select Medical
2.30
1.22
1.22
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
29.49
29.48

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Chemed Co. stock logo
CHE
Chemed
95.85%
Encompass Health Co. stock logo
EHC
Encompass Health
97.25%
Select Medical Holdings Co. stock logo
SEM
Select Medical
89.48%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Chemed Co. stock logo
CHE
Chemed
3.32%
Encompass Health Co. stock logo
EHC
Encompass Health
2.10%
Select Medical Holdings Co. stock logo
SEM
Select Medical
19.14%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Chemed Co. stock logo
CHE
Chemed
15,08715.14 million14.64 millionOptionable
Encompass Health Co. stock logo
EHC
Encompass Health
38,000100.68 million98.57 millionOptionable
Select Medical Holdings Co. stock logo
SEM
Select Medical
54,600130.03 million105.14 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
28110.27 million105.09 millionOptionable

EHC, SEM, VKTX, and CHE Headlines

Recent News About These Companies

2 Stocks That Could 10x by 2035

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Chemed logo

Chemed

NYSE:CHE
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Encompass Health logo

Encompass Health

NYSE:EHC
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions. It offers services through the Medicare program to federal government, managed care plans and private insurers, state governments, and other patients. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. The company was incorporated in 1984 and is based in Birmingham, Alabama.
Select Medical logo

Select Medical

NYSE:SEM
Select Medical Holdings Corporation, through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. It operates in four segments: Critical Illness Recovery Hospital, Rehabilitation Hospital, Outpatient Rehabilitation, and Concentra. The Critical Illness Recovery Hospital segment consists of hospitals that provide services for heart failure, infectious disease, respiratory failure and pulmonary disease, surgery requiring prolonged recovery, renal disease, neurological events, and trauma. The Rehabilitation Hospital segment offers therapy and rehabilitation treatments, including rehabilitative services for brain and spinal cord injuries, strokes, amputations, neurological disorders, orthopedic conditions, pediatric congenital or acquired disabilities, and cancer. The Outpatient Rehabilitation segment operates rehabilitation clinics that provide physical, occupational, and speech rehabilitation programs and services; and specialized programs, such as functional programs for work related injuries, hand therapy, post-concussion rehabilitation, pediatric and cancer rehabilitation, and athletic training services. The Concentra segment operates and provides occupational health centers, telemedicine platforms, onsite clinics, and contract services at employer worksites that deliver occupational health services, consumer health, physical therapy, and preventive care. Select Medical Holdings Corporation was founded in 1996 and is headquartered in Mechanicsburg, Pennsylvania.
Viking Therapeutics logo

Viking Therapeutics

NASDAQ:VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.